Efficacy of the neurokinin-1 receptor antagonist aprepitant in children with cyclical vomiting syndrome

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 3, 2014, Pages 309-317

  Cristofori, F ^a   Thapar, N ^a   Saliakellis, E ^a   Kumaraguru, N ^a   Elawad, M ^a   Kiparissi, F ^a   Koglmeier J ^a   Andrews, P ^b   Lindley, K J ^a   Borrelli, O ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT;

ADOLESCENT; ARTICLE; ASTHENIA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYCLICAL VOMITING SYNDROME; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HICCUP; HOSPITAL ADMISSION; HUMAN; INCREASED APPETITE; MALE; MIGRAINE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VOMITING;

ADOLESCENT; ANTIEMETICS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MORPHOLINES; NEUROKININ-1 RECEPTOR ANTAGONISTS; TREATMENT OUTCOME; VOMITING;

EID: 84904045235     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12822     Document Type: Article

References (37)

1. Li BUK, Misiewicz L,. Cyclic vomiting syndrome: a brain-gut disorder. Gastroenterol Clin North Am 2003; 32: 997-1019.
2. Lindley KJ, Andrews PL,. Pathogenesis and treatment of cyclical vomiting. J Pediatr Gastroenterol Nutr 2005; 41: S38-40.
3. Fitzpatrick E, Bourke B, Drumm B, et al,. The incidence of cyclic vomiting syndrome in children: population-based study. Am J Gastroenterol 2008; 103: 991-5.
4. Li BU, Balint JP,. Cyclic vomiting syndrome: evolution in our understanding of a brain-gut disorder. Adv Pediatr 2000; 47: 117-60.
5. Sudel B, Li BU,. Treatment options for cyclic vomiting syndrome. Curr Treat Options Gastroenterol 2005; 8: 387-95.
6. Li BU, Lefevre F, Chelimsky GG, et al,. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2008; 47: 379-93.
7. Lee LY, Abbott L, Mahlangu B, et al,. The management of cyclic vomiting syndrome: a systematic review. Eur J Gastroenterol Hepatol 2012; 24: 1001-6.
8. Albany C, Brames MJ, Fausel C, et al,. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier oncology group study. J Clin Oncol 2012; 30: 3998-4003.
9. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al,. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006; 17: 1000-6.
10. Herrstedt J, Muss HB, Warr DG, et al,. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005; 1: 1548-55.
11. Gore L, Chawla S, Petrilli A, et al,. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 2009; 52: 242-7.
12. Diemunsch P, Gan TJ, Philip BK, et al,. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery. Br J Anaesth 2007; 99: 202-11.
13. Habib AS, Keifer JC, Borel CO, et al,. A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy. Anesth Analg 2011; 112: 813-8.
14. Murphy C, Shah N, Milla P, et al,. NK1 receptor antagonism ameliorates nausea and emesis in typical and atypical variants of treatment refractory cyclical vomiting syndrome. J Pediatr Gastroenterol Nutr 2006; 42: E13.
15. Olson AD, Li BU,. The diagnostic evaluation of children with cyclic vomiting: a cost-effectiveness assessment. J Pediatr 2002; 141: 724-8.
16. Van Laere K, De Hoon J, Bormans G, et al,. Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. Oral aprepitant as assessed by PET imaging. Clin Pharmacol Ther 2012; 92: 243-5.
17. Venkatesan T, Tarbell S, Adams K, et al,. A survey of emergency department use in patients with cyclic vomiting syndrome. BMC Emerg Med 2010; 24: 4.
18. Hornby PJ,. Central neurocircuitry associated with emesis. Am J Med 2001; 111 (Suppl. 8A): 106S-12S.
19. Sanger GJ, Andrews PLR,. Treatment of nausea and vomiting: Gaps in our knowledge. Auton Neurosci 2006; 129: 3-16.
20. Stern RM, Koch KL, Andrews PLR,. Nausea: Mechanisms and Management. New York, USA: Oxford University Press, 2011. 462 pp. ISBN 978-0-19-517815-9.
21. Andrews PLR, Sanger GJ,. Nausea and the quest for the perfect anti-emetic. Eur J Pharmacol 2014; 722: 108-21.
22. Andrews P, Rudd JA,. The role of tachykinins and the tachykinins NK1 receptor in nausea and vomiting. In:, Holzer P, ed. Handbook of Experimental Pharmacology, Vol. 164. Berlin: Springer-Verlag, 2004; 359-440.
23. 1 receptors. Br J Pharmacol 1994; 115: 84-94.
24. Andrews PL, Okada F, Woods AJ, et al,. The emetic and anti-emetic effects of the capsaicin analogue resiniferatoxin in Suncus murinus, the house musk shrew. Br J Pharmacol 2000; 130: 1247-54.
25. dos Santos LV, Souza FH, Brunetto AT, et al,. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst 2012; 104: 1280-92.
26. Kovac AL,. Update on the management of postoperative nausea and vomiting. Drugs 2013; 73: 1525-47.
27. Smith AR, Repka TL, Weigel BJ,. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents. Pediatr Blood Cancer 2005; 45: 857-60.
28. Choi MR, Jiles C, Seibel NL,. Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV). J Pediatr Hematol Oncol 2010; 32: e268-71.
29. Drumm BR, Bourke B, Drummond J, et al,. Cyclical vomiting syndrome in children: a prospective study. Neurogastroenterol Motil 2012; 24: 922-7.
30. Tarbell SE, Li BU,. Health-related quality of life in children and adolescents with cyclic vomiting syndrome: a comparison with published data on youth with irritable bowel syndrome and organic gastrointestinal disorders. J Pediatr 2013; 163: 493-7.
31. Lordick F, Ehlken B, Ihbe-Heffinger A, et al,. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer 2007; 43: 299-307.
32. Annemans L, Strens D, Lox E, et al,. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Support Care Cancer 2008; 16: 905-15.
33. Jansen AC, van Aalst-Cohen ES, Hutten BA, et al,. Guidelines were developed for data collection from medical records for use in retrospective analyses. J Clin Epidemiol 2005; 58: 269-74.
34. Fernandes R, Ferreira JJ, Sampaio C,. The placebo response in studies of acute migraine. J Pediatr 2008; 152: 527-33.
35. Saps M, Youssef N, Miranda A, et al,. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology 2009; 137: 1261-9.
36. Fleisher DR, Matar M,. Cyclic vomiting syndrome: A report of 71 cases and literature review. J Pediatr Gastroenterol Nutr 1993; 17: 361-9.
37. Dignan F, Symon DNK, AbuArafeh I, et al,. The prognosis of cyclical vomiting syndrome. Arch Dis Child 2001; 84: 55-7.